GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (FRA:PV3) » Definitions » Inventories, Raw Materials & Components

EyePoint Pharmaceuticals (FRA:PV3) Inventories, Raw Materials & Components : €1.20 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is EyePoint Pharmaceuticals Inventories, Raw Materials & Components?

EyePoint Pharmaceuticals's inventories, raw materials & components for the quarter that ended in Dec. 2023 was €1.20 Mil.

EyePoint Pharmaceuticals's quarterly raw materials increased from Jun. 2023 (€1.05 Mil) to Sep. 2023 (€1.19 Mil) and increased from Sep. 2023 (€1.19 Mil) to Dec. 2023 (€1.20 Mil).

EyePoint Pharmaceuticals's annual raw materials declined from Dec. 2021 (€2.41 Mil) to Dec. 2022 (€1.33 Mil) and declined from Dec. 2022 (€1.33 Mil) to Dec. 2023 (€1.20 Mil).


EyePoint Pharmaceuticals Inventories, Raw Materials & Components Historical Data

The historical data trend for EyePoint Pharmaceuticals's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Inventories, Raw Materials & Components Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.33 2.19 2.41 1.33 1.20

EyePoint Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.19 1.05 1.19 1.20

EyePoint Pharmaceuticals Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


EyePoint Pharmaceuticals (FRA:PV3) Business Description

Industry
Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (FRA:PV3) Headlines

No Headlines